In spite of the decreased incidence of colon cancer (CC) in recent 10 years, it remains the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States.1 But in China, colon cancer is on the rise, which is the fourth most commonly diagnosed cancers among men and the third one among women.2 Approximately 20%‐25% of patients diagnosed with colon cancer present with metastatic disease and result in a poor prognosis.3, 4, 5 Cetuximab is a chimeric monoclonal antibody directed against EGFR that inhibits its downstream signaling pathways. The gene discussed is EGFR; the disease is cancer.